NCT00002077已完成不适用
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 试验地点
- 4
研究概览
简要总结
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Lack of satisfactory response will allow increase of dose. Both newly diagnosed and relapsed patients are eligible.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Antivirals such as zidovudine (AZT).
- •Prophylaxis for Pneumocystis carinii pneumonia (including aerosolized pentamidine).
- •Concurrent Treatment:
- •Radiation therapy for mucocutaneous Kaposi's sarcoma.
- •Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian.
- •Patient's treatment status must be one of the following:
- •No prior systemic antifungal therapy for cryptococcosis.
- •Relapse after prior therapy. The success of prior therapy must have been documented by negative CSF culture at the end of therapy. Following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into the study.
- •Prior Medication:
- •Antivirals such as zidovudine (AZT).
- •Prophylaxis for Pneumocystis carinii pneumonia (including aerosolized pentamidine).
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
- •A history of allergy to or intolerance of imidazoles or azoles.
- •Moderate or severe liver disease defined by specified lab values.
- •Life expectancy of < 2 weeks.
- •Concurrent Medication:
- •Coumarin-type anticoagulants.
- •Oral hypoglycemics.
- •Barbiturates.
- •Phenytoin.
- •Immunostimulants.
- •Investigational drugs or approved (licensed) drugs for investigational indications other than aerosolized pentamidine.
- •Concurrent Treatment:
- •Lymphocyte replacement.
- •Patients with the following are excluded:
- •Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
- •A history of allergy to or intolerance of imidazoles or azoles.
- •Moderate or severe liver disease defined by specified lab values.
- •Life expectancy of < 2 weeks.
- •Prior Medication:
- •Coumarin-type anticoagulants.
- •Oral hypoglycemics.
- •Barbiturates.
- •Phenytoin.
- •Immunostimulants.
- •Investigational drugs or approved (licensed) drugs for investigational indications other than aerosolized pentamidine.
- •Prior Treatment:
- •Lymphocyte replacement.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal MeningitisMeningitis, CryptococcalHIV InfectionsNCT00002040Pfizer
已完成
不适用
Intravenous Fluconazole prophylaxis in preterm neonatesCandidial sepsis.Neonatal candidiasisIRCT2014051411499N1Research Vice-Canceller of Tabriz University of Medical Sciences100
已完成
1 期
Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsHealthy SubjectsNCT04850651Jiangsu HengRui Medicine Co., Ltd.18
已完成
4 期
A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent ThrushCandidiasis, OralHIV InfectionsNCT00000951National Institute of Allergy and Infectious Diseases (NIAID)948
已完成
1 期
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With OsteoporosisSpinal FracturesOsteoporosisNCT02566655Red de Terapia Celular10